SAN JOSE, Calif., Oct. 25, 2019 /PRNewswire/ -- Anixa
Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused
on harnessing the body's immune system in the fight against cancer,
today announced its collaboration with Urology San Antonio, PA in
Anixa's ongoing Cchek™ prostate cancer study.
Urology San Antonio, PA joins a
large and growing team of collaborators advancing the Cchek™ liquid
biopsy technology toward commercialization.
Study enrollment will be led by board-certified urologist Dr.
David R. Talley.
"We are excited to join Anixa's Cchek™ prostate cancer study,
and through this collaboration we hope to improve patient care,"
stated Dr. Talley. "Prostate cancer is one of the most common
types of cancer in men, and if detected early, has a better chance
of successful treatment. While several advancements have been
made in recent years, there is much room for improvement in
detecting the disease early and efficiently."
Dr. Amit Kumar, Anixa's Chief
Executive Officer, stated, "We are pleased to have Urology San
Antonio join our Cchek™ prostate cancer study. The continued
addition of influential physicians and urology practices to our
team of collaborators is key to the eventual commercialization of
our Cchek™ Prostate Cancer Confirmation test. We are
confident this technology utilizing flow cytometry coupled with
artificial intelligence to detect cancer early will make a
significant impact in the overall testing paradigm."
About Cchek™
Cchek™ is an early cancer detection
technology, which measures a patient's immunological response to a
malignancy by analyzing immune system cells in peripheral blood.
The goal is to utilize the technology to determine a
patient's cancer status from a simple blood draw, eliminating the
need for a biopsy, which can be an expensive, painful and invasive
procedure. Further, conventional methods using current cancer
screening tests often lack accuracy and reliability. Anixa's
orthogonal approach using flow cytometry coupled with artificial
intelligence provides an alternative method with greater
affordability, efficacy and efficiency. To date, Anixa has
successfully used Cchek™ to detect the presence of 20 different
cancers including lung, colon, breast and prostate. The
robust cancer detection performance of Cchek™ makes it a platform
from which multiple cancer diagnostic tests may be developed.
The first such test, a prostate cancer confirmation test, is slated
for commercial launch by the end of 2019.
About Urology San Antonio, PA
Urology San Antonio, PA, established in 1996, is the
largest urology practice in South
Texas with thirty physicians and over 270 employees at seven
urology clinics. Urology San Antonio's strategic and
day-to-day operations are guided by three core principles:
provide excellent patient care and service, offer excellent quality
of life for partners and employees, and create profit with
integrity.
About Anixa Biosciences, Inc.
Anixa is a
publicly-traded biotechnology company focused on harnessing the
body's immune system in the fight against cancer. Anixa is
developing a cancer immunotherapy program, which uses chimeric
endocrine receptor T-cell (CER-T) technology, a novel type of
CAR-T. Its Cchek™ liquid biopsy technology is a series
of inexpensive non-invasive blood tests for early detection of
solid tumors based on the body's immune response to the presence of
a malignancy. This technology enables cancer detection in its
earliest stages in efforts to treat patients when the disease is
most curable. Anixa continually examines emerging
technologies in complementary fields for further development and
commercialization. Additional information is available at
www.anixa.com.
Forward-Looking Statements: Statements
that are not historical fact may be considered forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are not
statements of historical facts, but rather reflect Anixa's current
expectations concerning future events and results. We
generally use the words "believes," "expects," "intends," "plans,"
"anticipates," "likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including those concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, those
factors set forth in "Item 1A - Risk Factors" and other sections of
our most recent Annual Report on Form 10-K as well as in our
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
We undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law. You
are cautioned not to unduly rely on such forward-looking statements
when evaluating the information presented in this press
release.
Anixa contact:
Mike Catelani
mcatelani@anixa.com
408-708-9808
Tiberend Strategic Advisors, Inc.
Sharen Tilman (Investors)
stilman@tiberend.com
646-604-5149
Johanna Bennett (Media)
jbennett@tiberend.com
212-375-2686
View original content to download
multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-announces-collaboration-with-urology-san-antonio-on-cchek-prostate-cancer-study-300945349.html
SOURCE Anixa Biosciences, Inc.